Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 3, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of shareholding changes within a specific employee retirement plan and does not contain financial performance data.
Material Changes
The filing details changes in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan") due to fund movements:
- December 29, 2005: Holdings decreased from 18,452,425 to 18,437,908 ADRs at an average price of $51.19.
- December 30, 2005: Holdings increased from 18,437,908 to 18,475,715 ADRs at an average price of $50.90.
Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share transactions described above.
Key Facts for Investor Verification
- Verify the total aggregate holdings of the GlaxoSmithKline US Retirement Savings Plan following the December 2005 movements.
- Confirm the specific beneficial ownership status of Directors Dr. J P Garnier and Dr. T Yamada relative to the Plan's holdings.
- Note that this filing does not reflect operational or financial performance for the period.